76 related articles for article (PubMed ID: 20435577)
1. In vitro synergistic activity of combined piperacillin and tobramycin against clinical strains of Achromobacter xylosoxidans.
Duez JM; Hadjait-Savioz M; Siebor E; Astruc K; Bador J; Péchinot A; Sixt N; Huet F; Neuwirth C
J Chemother; 2010 Apr; 22(2):139-41. PubMed ID: 20435577
[No Abstract] [Full Text] [Related]
2. Properties of Achromobacter xylosoxidans highly resistant to aminoglycoside antibiotics.
Nakamoto S; Goda N; Hayabuchi T; Tamaki H; Ishida A; Suzuki A; Nakano K; Yui S; Katsumata Y; Yamagami Y; Burioka N; Chikumi H; Shimizu E
Jpn J Antibiot; 2016 Apr; 69(2):113-8. PubMed ID: 27544979
[TBL] [Abstract][Full Text] [Related]
3. Enterococci and aminoglycosides: evaluation of susceptibility and synergism of their combination with piperacillin.
Stefani S; Russo G; Nicolosi VM; Nicoletti G
Chemioterapia; 1987 Feb; 6(1):12-6. PubMed ID: 3103929
[TBL] [Abstract][Full Text] [Related]
4. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
Zhanel GG; Mayer M; Laing N; Adam HJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):2228-30. PubMed ID: 16723591
[TBL] [Abstract][Full Text] [Related]
5. Clinical Features, Antibiotic Susceptibility Profiles, and Outcomes of Infectious Keratitis Caused by Achromobacter xylosoxidans.
Spierer O; Monsalve PF; OʼBrien TP; Alfonso EC; Gologorsky D; Miller D
Cornea; 2016 May; 35(5):626-30. PubMed ID: 26989957
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparison of aminoglycoside activities and their synergistic action with piperacillin.
Hoogkamp-Korstanje JA
Infection; 1985; 13(1):39-42. PubMed ID: 3988352
[TBL] [Abstract][Full Text] [Related]
7. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.
Bador J; Amoureux L; Blanc E; Neuwirth C
Antimicrob Agents Chemother; 2013 Jan; 57(1):603-5. PubMed ID: 23089757
[TBL] [Abstract][Full Text] [Related]
8. Investigation of hospital-acquired infections due to Achromobacter xylosoxidans in a tertiary care hospital in India.
Kumar A; Ray P; Kanwar M; Sethi S; Narang A
J Hosp Infect; 2006 Feb; 62(2):248-50. PubMed ID: 16289456
[No Abstract] [Full Text] [Related]
9. Achromobacter xylosoxidans meningitis in an immunosuppressed patient.
Bellissimo F; Pinzone MR; Tosto S; Nunnari G; Cacopardo B
QJM; 2014 Jan; 107(1):65-6. PubMed ID: 23970185
[No Abstract] [Full Text] [Related]
10. AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand.
Pongchaikul P; Santanirand P; Antonyuk S; Winstanley C; Darby AC
FEMS Microbiol Lett; 2020 Jul; 367(14):. PubMed ID: 32592387
[TBL] [Abstract][Full Text] [Related]
11. [Achromobacter xylosoxidans colonisation in bronchiectasis].
Gázquez G
Enferm Infecc Microbiol Clin; 2010 Dec; 28(10):758-9; author reply 759. PubMed ID: 20846757
[No Abstract] [Full Text] [Related]
12. Achromobacter xylosoxidans mesh related infection: a case of delayed diagnosis and management.
Gupta V; Nirkhiwale S; Gupta P; Phatak S
J Infect; 2012 Mar; 64(3):e1-5. PubMed ID: 21959012
[TBL] [Abstract][Full Text] [Related]
13. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
[TBL] [Abstract][Full Text] [Related]
14. Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137.
Amoureux L; Sauge J; Sarret B; Lhoumeau M; Bajard A; Tetu J; Bador J; Neuwirth C;
J Cyst Fibros; 2019 Nov; 18(6):804-807. PubMed ID: 31104975
[TBL] [Abstract][Full Text] [Related]
15. Bilateral simultaneous Achromobacter xylosoxidans keratitis following penetrating keratoplasty.
Srinivasan S; McAllum P; Poutanen SM; Slomovic AR
J Cataract Refract Surg; 2006 Dec; 32(12):2149-52. PubMed ID: 17138001
[TBL] [Abstract][Full Text] [Related]
16. [In vitro study of the synergistic effect of cefotiam- aminoglycoside combinations on strains of low susceptibility to this cephalosporin].
Husson MO; Izard D; Leclerc H
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):466-8. PubMed ID: 3911141
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Achromobacter xylosoxidans bacteremia in northern Taiwan.
Shie SS; Huang CT; Leu HS
J Microbiol Immunol Infect; 2005 Aug; 38(4):277-82. PubMed ID: 16118676
[TBL] [Abstract][Full Text] [Related]
18. Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.
Hu Y; Zhu Y; Ma Y; Liu F; Lu N; Yang X; Luan C; Yi Y; Zhu B
Antimicrob Agents Chemother; 2015 Feb; 59(2):1152-61. PubMed ID: 25487802
[TBL] [Abstract][Full Text] [Related]
19. [Achromobacter xylosoxidans].
Sakurad A
Rev Chilena Infectol; 2012 Aug; 29(4):453-4. PubMed ID: 23096549
[No Abstract] [Full Text] [Related]
20. [Sensitivity in vitro of 192 Proteus strains to several aminoglycosides].
Thaller MC; Berchicchi R; Berlutti F; Maragoni F; Dainelli B
Ann Sclavo; 1981; 23(1):57-63. PubMed ID: 7294918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
